Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLY R AMANN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1134116783
CMS profile
187578
Location
ROY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$352.65

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $352.65 23

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLY R AMANN

NPI 1134116783 · CMS profile ID 187578

Allopathic & Osteopathic Physicians / Family Medicine

ROY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLY R AMANN, NPI 1134116783, CMS profile ID 187578. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). KELLY R AMANN, NPI 1134116783, CMS profile ID 187578. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
KELLY R AMANN, NPI 1134116783, CMS profile ID 187578, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1134116783?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $352.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $17.2812/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 857147265 CMS
Eisai Inc. $12.8312/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751244311 CMS
Amarin Pharma Inc. $15.6912/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740071717 CMS
Amarin Pharma Inc. $18.0011/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739929253 CMS
Amarin Pharma Inc. $18.9511/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739952083 CMS
QIAGEN, LLC $14.5610/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752481511 CMS
AstraZeneca Pharmaceuticals LP $11.5610/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735825927 CMS
Vanda Pharmaceuticals Inc. $26.2010/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735124293 CMS
Amarin Pharma Inc. $17.1810/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740071719 CMS
Astellas Pharma US Inc $13.4009/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718294175 CMS
Amarin Pharma Inc. $16.8309/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739948073 CMS
QIAGEN, LLC $14.0209/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752480359 CMS
Amarin Pharma Inc. $22.9208/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740071715 CMS
GlaxoSmithKline, LLC. $11.6207/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738968269 CMS
Eisai Inc. $11.1407/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751212307 CMS
Teva Pharmaceuticals USA, Inc. $13.4607/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749484505 CMS
GlaxoSmithKline, LLC. $17.4303/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738855539 CMS
Amgen Inc. $11.3603/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741174413 CMS
Lilly USA, LLC $11.4003/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728505817 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747118571 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0602/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720643115 CMS
AstraZeneca Pharmaceuticals LP $12.6902/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736372911 CMS
SANOFI-AVENTIS U.S. LLC $13.5101/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744181913 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $481.24 35
PY2020 $352.65 23
PY2021 $704.02 48
PY2022 $510.64 34
PY2023 $475.66 30
PY2024 $710.07 47
PY2025 $468.94 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $267,494.93 21
PY2024 Principal investigator $509,633.49 63
PY2023 Principal investigator $838,851.01 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $21,401.29 12/26/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042051945
Principal investigator 1 Genentech, Inc. $2,349.00 12/22/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288569
Principal investigator 1 ModernaTX, Inc. $1,340.00 12/20/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051863
Principal investigator 1 ModernaTX, Inc. $1,340.00 12/20/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051875
Principal investigator 1 ModernaTX, Inc. $27,096.66 12/13/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051837
Principal investigator 1 Genentech, Inc. $14,094.00 12/08/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288601
Principal investigator 1 ModernaTX, Inc. $196,378.45 11/29/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042051589
Principal investigator 1 Genentech, Inc. $2,349.00 11/24/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288097
Principal investigator 1 ModernaTX, Inc. $16,000.00 11/24/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042051077
Principal investigator 1 ModernaTX, Inc. $3,100.00 11/24/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042051083
Principal investigator 1 Genentech, Inc. $37,584.00 11/16/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288441
Principal investigator 1 Genentech, Inc. $4,698.00 11/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288151
Principal investigator 1 Genentech, Inc. $35,235.00 11/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288311
Principal investigator 1 ModernaTX, Inc. $12,363.30 11/01/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051043
Principal investigator 1 Genentech, Inc. $32,886.00 10/23/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040287545
Principal investigator 1 Mylan Specialty L.P. $1,396.55 10/17/2023 Non-covered Recipient Entity
Ogden Clinic
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038209599
Principal investigator 1 Genentech, Inc. $4,698.00 09/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040285267
Principal investigator 1 Genentech, Inc. $2,736.00 09/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040284612
Principal investigator 1 ModernaTX, Inc. $44,114.15 08/30/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042050995
Principal investigator 1 ModernaTX, Inc. $162.00 08/30/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051001
Principal investigator 1 Genentech, Inc. $9,396.00 08/24/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040285411
Principal investigator 1 Genentech, Inc. $750.00 08/21/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040284485
Principal investigator 1 Genentech, Inc. $16,443.00 08/21/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040286059
Principal investigator 1 Genentech, Inc. $14,094.00 08/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040286723
Principal investigator 1 Genentech, Inc. $4,698.00 08/08/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040285050
Principal investigator 1 ModernaTX, Inc. $1,340.00 08/02/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051535
Principal investigator 1 Genentech, Inc. $2,349.00 07/27/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040284579
Principal investigator 1 ModernaTX, Inc. $10,657.58 07/21/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042050965
Principal investigator 1 Mylan Specialty L.P. $13,324.00 07/17/2023 Non-covered Recipient Entity
Ogden Clinic
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038209593
Principal investigator 1 Genentech, Inc. $900.00 07/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040284063
Principal investigator 1 ModernaTX, Inc. $74,565.63 07/05/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042050927
Principal investigator 1 Genentech, Inc. $13,500.00 06/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040283691
Principal investigator 1 ModernaTX, Inc. $10,000.00 05/26/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042050855
Principal investigator 1 ModernaTX, Inc. $2,500.00 05/26/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042050861
Principal investigator 1 ModernaTX, Inc. $1,150.00 05/26/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042050867
Principal investigator 1 ModernaTX, Inc. $8,650.00 05/10/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051463
Principal investigator 1 ModernaTX, Inc. $1,340.00 05/10/2023 Non-covered Recipient Entity
Ogden Clinic - Grand View
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042051469
Principal investigator 1 Abbott Laboratories $63,797.40 05/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A or Influenza B No dispute reported 06/30/2026 1039667169
Principal investigator 1 Abbott Laboratories $63,797.40 05/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A or Influenza B No dispute reported 06/30/2026 1039667177
Principal investigator 1 Abbott Laboratories $20,341.20 05/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A or Influenza B No dispute reported 06/30/2026 1039667189
Principal investigator 1 Abbott Laboratories $31,436.40 05/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A or Influenza B No dispute reported 06/30/2026 1039667199
Principal investigator 1 Abbott Laboratories $500.00 03/17/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A or Influenza B No dispute reported 06/30/2026 1039667475
Principal investigator 1 Abbott Laboratories $12,000.00 01/19/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A or Influenza B No dispute reported 06/30/2026 1039667157